Avadel Pharmaceuticals 053332BC5 Bond
| AVDL Stock | USD 11.22 0.44 3.77% |
Avadel Pharmaceuticals holds a debt-to-equity ratio of 2.627. At this time, Avadel Pharmaceuticals' Short and Long Term Debt Total is quite stable compared to the past year. Long Term Debt is expected to rise to about 110.6 M this year, although the value of Short Term Debt will most likely fall to about 1.8 M. . Avadel Pharmaceuticals' financial risk is the risk to Avadel Pharmaceuticals stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Avadel Pharmaceuticals' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Avadel Pharmaceuticals' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Avadel Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Avadel Pharmaceuticals' stakeholders.
For most companies, including Avadel Pharmaceuticals, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Avadel Pharmaceuticals PLC, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Avadel Pharmaceuticals' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 15.0486 | Book Value 0.976 | Operating Margin (0.31) | Profit Margin (1.12) | Return On Assets (0.34) |
Avadel |
Given the importance of Avadel Pharmaceuticals' capital structure, the first step in the capital decision process is for the management of Avadel Pharmaceuticals to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Avadel Pharmaceuticals PLC to issue bonds at a reasonable cost.
| Popular Name | Avadel Pharmaceuticals AZO 45 01 FEB 28 |
| Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
| Equity ISIN Code | US05337M1045 |
| Bond Issue ISIN Code | US053332BC52 |
| S&P Rating | Others |
| Maturity Date | Others |
| Issuance Date | Others |
Avadel Pharmaceuticals Outstanding Bond Obligations
| Boeing Co 2196 | US097023DG73 | Details | |
| HSBC Holdings PLC | US404280DR76 | Details | |
| AZO 475 01 AUG 32 | US053332BB79 | Details | |
| AZO 45 01 FEB 28 | US053332BC52 | Details | |
| US053332BA96 | US053332BA96 | Details | |
| AZO 475 01 FEB 33 | US053332BD36 | Details | |
| US053332AY81 | US053332AY81 | Details | |
| AUTOZONE INC | US053332AZ56 | Details | |
| AUTOZONE INC 375 | US053332AV43 | Details | |
| US053332AW26 | US053332AW26 | Details | |
| AUTOZONE INC 3125 | US053332AT96 | Details | |
| AUTOZONE INC 325 | US053332AR31 | Details | |
| MGM Resorts International | US552953CD18 | Details | |
| AerCap Global Aviation | US00773HAA59 | Details |
Understaning Avadel Pharmaceuticals Use of Financial Leverage
Leverage ratios show Avadel Pharmaceuticals' total debt position, including all outstanding obligations. In simple terms, high financial leverage means that the cost of production, along with the day-to-day running of the business, is high. Conversely, lower financial leverage implies lower fixed cost investment in the business, which is generally considered a good sign by investors. The degree of Avadel Pharmaceuticals' financial leverage can be measured in several ways, including ratios such as the debt-to-equity ratio (total debt / total equity), or the debt ratio (total debt / total assets).
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 35.4 M | 38.3 M | |
| Net Debt | 4.2 M | 4 M | |
| Short Term Debt | 1.9 M | 1.8 M | |
| Long Term Debt | 105.4 M | 110.6 M | |
| Short and Long Term Debt | 33.9 M | 35.6 M | |
| Long Term Debt Total | 163.8 M | 171.9 M | |
| Net Debt To EBITDA | (0.03) | (0.03) | |
| Debt To Equity | 0.38 | 0.36 | |
| Interest Debt Per Share | 0.54 | 0.77 | |
| Debt To Assets | 0.20 | 0.18 | |
| Long Term Debt To Capitalization | 0.27 | 0.25 | |
| Total Debt To Capitalization | 0.28 | 0.26 | |
| Debt Equity Ratio | 0.38 | 0.36 | |
| Debt Ratio | 0.20 | 0.18 | |
| Cash Flow To Debt Ratio | (3.81) | (3.62) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Avadel Pharmaceuticals Fundamentals Over Time. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 1.036 | Quarterly Revenue Growth 26.743 | Return On Assets (0.34) | Return On Equity (1.00) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.